Armine K. Smith

Armine K. Smith

Auto-generated profile, based on publicly available information

Armine K. Smith

Johns Hopkins University, Baltimore, MD

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
SASarah Azari
Sarah Azari
SISamita Islam
Samita Islam
MKMatthew Klein
Matthew Klein
MWMichael Whalen
Michael Whalen

17 June 2022 in Case Reports in Urology
Verified
Journal Article
Open access
PDF file
ASAmanda Smart
Amanda Smart
MWMichael Wynne
Michael Wynne
EBEzra Baraban
Ezra Baraban
YGYasser Ged
Yasser Ged
ASArmine Smith
Armine Smith
Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. To date, there are only about 40 reported cases of RCC with solitary bladder metastasis. The following report contributes to this limited data set of patients with RCC who develop solitary metastasis to the bladder. A 69-year-old male presented with occasional gross hematuria and was found to have a left renal mass infiltrating the collecting system. Ureteroscopic biopsy revealed clear cell RCC, and the patient subsequently underwent radical left nephrectomy. Eight months after nephrectomy, the patient presented to the clinic with gross hematuria. In-office cystoscopy demonstrated a nodular lesion in the bladder arising from the left ureteral orifice. The patient underwent transurethral resection of the bladder mass and pathology demonstrated clear cell RCC. Subsequent imaging showed no evidence of metastatic disease. Five months after transurethral resection, the patient was found to have a left distal ureteral mass and underwent left ureterectomy with partial cystectomy. Pathology again demonstrated clear cell RCC. RCC with solitary metastasis to the bladder is rare, and there are no targeted guideline recommendations for management. Per standard of care, patients with painless hematuria and risk factors for malignancy should undergo cystoscopy. In patients with a history of RCC, metastasis to the bladder should be considered in the differential diagnosis. Patients with metastatic RCC to the bladder should undergo a thorough work-up for additional sites of metastasis. In patients with RCC who develop solitary bladder metastasis amenable to resection following nephrectomy, there is a lack of evidence to guide therapy and a multidisciplinary discussion is warranted. However, if the tumor is amenable to resection, metastasectomy is a reasonable therapeutic approach and offers the patient an improved quality of life and an opportunity for remission.

1 October 2025 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
AMAndres Matoso
Andres Matoso
SKSonia Kamanda
Sonia Kamanda
SPSunil Patel
Sunil Patel
MMMeghan McNamara
Meghan McNamara
SWShirley Wang
Shirley Wang
ASArmine Smith
Armine Smith
Background: In female patients undergoing cystectomy where orthotopic bladder reconstruction is not an option, urethrectomy is typically performed. Unlike in males, female urethrectomy carries a risk of damaging clitoral structures and nerves, potentially contributing to post-cystectomy sexual dysfunction. This study evaluates overall survival in women undergoing cystectomy with versus without urethrectomy. Methods: A retrospective review of electronic medical records from 2000 to 2023 was conducted. Radical cystectomy specimens were reviewed for surgical details, tumor characteristics, urethral involvement, and urethrectomy status. Institutional criteria required urethrectomy in patients receiving neobladder reconstruction. Results: Among 347 women who underwent cystectomy, 298 received urethrectomy and 49 did not. The mean age was 65.4 years. Urethral involvement was present in 15 cases (7%). One patient with a neobladder and positive urethral margin remained disease-free at 5 years. At the last follow-up, 54.2% of patients with urethrectomy and 61.2% without urethrectomy showed no evidence of disease. A total of 76 patients (26.5%) were alive with disease, 62 (20.8%) in the urethrectomy group and 14 (28.6%) in the non-urethrectomy group. Kaplan-Meier analysis showed mean overall survival of 246.9 months with urethrectomy vs. 173.9 months without. Propensity score matching (2:1) included 70 urethrectomy and 35 non-urethrectomy patients. Kaplan-Meier and Cox regression analyses showed no significant survival difference (P=0.07). Conclusions: Urethra-sparing cystectomy in women may be oncologically safe when no urethral involvement is present and should be considered to preserve sexual function.



1 October 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
VNVivek Nimgaonkar
Vivek Nimgaonkar
AAAlyssa Arbuiso
Alyssa Arbuiso
EVEvangelia Vlachou
Evangelia Vlachou
BJBurles Avner Johnson
Burles Avner Johnson
ASArmine Smith
Armine Smith
JHJean Hoffman-Censits
Jean Hoffman-Censits
PURPOSE: Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers. We sought to explore whether ctDNA dynamics is associated with survival outcomes. METHODS: This retrospective study included patients with la/mUC receiving first-line EVP, who had plasma ctDNA collected using the Signatera assay within 3 months after treatment initiation. Associations between ctDNA clearance and overall survival (OS) and progression-free survival (PFS) were assessed using multivariable time-dependent Cox proportional hazard (CPH) models and landmark analyses at 1, 2, and 3 months after EVP initiation. Longitudinal ctDNA trends were examined in a subpopulation with baseline ctDNA values collected. RESULTS: Fifty-eight patients were included. In multivariable time-dependent CPH models, ctDNA clearance was associated with both OS (hazard ratio [HR], 0.04 [95% CI, 0.01 to 0.24], P < .001) and PFS (HR, 0.09 [95% CI, 0.02 to 0.32], P < .001). In landmark analyses, ctDNA clearance was associated with longer OS and PFS at 2 months (log-rank test P = .003, P < .001, respectively). Among patients with baseline ctDNA (n = 42), 69% achieved ctDNA clearance after EVP initiation, whereas just 14% (n = 6) never had a decrease in ctDNA. The median time to clearance of ctDNA was 1.41 months (IQR, 0.85-1.94). CONCLUSION: While primarily hypothesis-generating, this study suggests that patients with la/mUC treated with first-line EVP frequently and rapidly clear ctDNA. Clearance of ctDNA in this population is associated with longer survival and merits further study.